Gonadorelin
Also known as: Cystorelin, Factrel, GnRH, Gonadorelin, Gonadorelin acetate, Gonadotropin‑releasing hormone, Kryptocur, LHRH, Lutrepulse
Source Gonadorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Gonadorelin is a synthetic analogue of the natural gonadotropin‑releasing hormone (GnRH) peptide. It is approved for prescription use and is administered via intranasal, intravenous, or subcutaneous routes. The compound has been investigated as one of many hormonal approaches for premenstrual syndrome (PMS), but the systematic review cited does not provide specific efficacy or safety data for this indication.
Mechanism of Action
Gonadorelin belongs to the GnRH agonist class. It binds to GnRH receptors in the anterior pituitary, initially stimulating the release of luteinising hormone (LH) and follicle‑stimulating hormone (FSH). With continued exposure, the pituitary becomes desensitised, leading to reduced downstream gonadal hormone production. This modulation of the hypothalamic‑pituitary‑gonadal axis underlies its therapeutic potential in hormone‑related conditions.
What the Research Shows
A 2007 systematic review of treatments for premenstrual syndrome listed gonadorelin analogues among a broad range of pharmacologic and non‑pharmacologic options. The review incorporated 52 studies covering many interventions, but it did not isolate data on gonadorelin's efficacy, dosage, or adverse‑event profile. Consequently, the evidence base for gonadorelin in PMS remains undefined within this source, and no quantitative conclusions about benefit or risk can be drawn from the cited literature.
Reported Benefits
Potential benefits of gonadorelin stem from its ability to alter pituitary gonadotropin output, which could theoretically alleviate hormone‑driven PMS symptoms. However, the systematic review provides no direct evidence of symptom reduction or clinical improvement, so any benefit remains speculative and unverified in the cited data.
Limitations of the Evidence
The primary limitation is the absence of specific trial results for gonadorelin in the PMS review; the compound is merely mentioned among many treatments. Without dedicated randomized trials or outcome measures, the magnitude of effect, optimal dosing, and comparative efficacy cannot be assessed. The overall evidence is therefore insufficient to support clinical use for PMS.
Safety Considerations
The systematic review does not report safety outcomes for gonadorelin analogues in the context of PMS. As a GnRH agonist, known class‑related adverse effects may include transient hormonal fluctuations, injection‑site reactions, and headache, but these are not documented in the cited source. Caution is warranted pending dedicated safety data.
How It Is Administered
Gonadorelin is formulated for intranasal, intravenous, and subcutaneous administration. The specific formulation (e.g., spray, injection) varies by product, but the routes are limited to these three methods as indicated in the structured data.
Routes of Administration
Goals & Uses
- Stimulate LH and FSH releaseEndocrine ActivationHigh
- Treatment of hypogonadotropic hypogonadism (male)EndocrinologyModerate
- Treatment of hypothalamic amenorrhea / induction of ovulationReproductive EndocrinologyHigh
- Trigger ovulation in assisted reproductionTherapeuticModerate
- Preservation of testicular function during exogenous androgen usePerformance / Andrology (off Label)Low
- Diagnostic assessment of pituitary gonadotropin reserveDiagnosticHigh
- Pituitary function diagnostic testDiagnosticHigh
- Cryptorchidism treatmentPediatric UrologyModerate
Contraindications
- Known hypersensitivity to gonadorelin or formulation excipientsAllergicHigh
- Conditions exacerbated by LH/FSH stimulation (e.g., hormone-sensitive tumors)OncologicHigh
- Hypersensitivity to gonadorelin or GnRH analoguesAllergy / ImmunologicHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
- Estrogen‑dependent neoplasms (e.g., breast, endometrial cancer)OncologicModerate
- Polycystic ovary syndrome (PCOS) in ovulation induction contextReproductiveModerate
Adverse Effects
- Injection site reactionsLocalCommon
- Multiple gestationReproductiveUncommon
- Anaphylaxis / hypersensitivityImmunologicRare
- Injection site painLocalCommonPain at the injection site
- HeadacheNeurologicUncommonPain in the head or upper neck
- FlushingVascularUncommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Ovarian hyperstimulation syndrome (OHSS)ReproductiveUncommon
Drug Interactions
- Exogenous androgens / anabolic steroidsModerate
- Estrogen‑containing oral contraceptivesModerate
- GnRH antagonists (e.g., cetrorelix, ganirelix)High
- Dopamine agonists (e.g., bromocriptine)Moderate
- DigoxinLow
- Dopamine agonists (e.g., bromocriptine, cabergoline)Low
Population Constraints
- Pediatric patientsAgeRelative
- Patients with pituitary tumorsOncologic / EndocrinologicRelative
- Pediatric patients (prepubertal)AgeRelative
- Pregnant womenReproductiveAbsolute
- Patients with ovarian cysts or enlarged ovariesReproductiveRelative
Regulatory Status
- European UnionApprovedApproved: diagnostic testing of pituitary functionAuthorized in several member states for similar diagnostic purposes.
- United StatesApprovedApproved: diagnostic testing of pituitary gonadotropin reserve, off‑label ovulation triggerMarketed as Gonadorelin acetate injection; FDA‑approved for diagnostic use.
- United KingdomApprovedApproved: diagnostic testing of pituitary gonadotropin reserveAvailable under the Human Medicines Regulations for diagnostic use.
Approved in the United States and several EU countries for diagnostic use; therapeutic indications are limited and often off‑label.
Evidence & Sources
- Journal ArticleHighKwan I, Onwude JL2007-01-01T00:00:00.000000Z
Frequently Asked Questions
Is gonadorelin approved for treating premenstrual syndrome?
No. While gonadorelin is an approved prescription drug, the cited systematic review does not indicate regulatory approval or specific endorsement for premenstrual syndrome.
How does gonadorelin work in the body?
It acts as an agonist at GnRH receptors in the pituitary, initially boosting LH and FSH release, then leading to receptor desensitisation and reduced downstream gonadal hormone production.
What evidence exists for gonadorelin's effectiveness in PMS?
The 2007 review lists gonadorelin among many PMS interventions but provides no separate efficacy data, making the evidence for its benefit in PMS currently lacking.
Are there known side effects of gonadorelin?
The review does not detail side effects for gonadorelin in PMS. General GnRH‑agonist class effects can include hormonal swings and injection‑site discomfort, but specific safety data are not presented.
What forms can gonadorelin be given in?
Gonadorelin can be administered intranasally, intravenously, or subcutaneously, according to the approved formulations.
What is Gonadorelin?
Gonadorelin is a synthetic analogue of the natural gonadotropin‑releasing hormone (GnRH) peptide. It is approved for prescription use and is administered via intranasal, intravenous, or subcutaneous routes. The compound has been investigated as one of many hormonal approaches for premenstrual syndrome (PMS), but the systematic review cited does not provide specific efficacy or safety data for this indication.
What is Gonadorelin used for?
Gonadorelin is educationally associated with: Stimulate LH and FSH release, Treatment of hypogonadotropic hypogonadism (male), Treatment of hypothalamic amenorrhea / induction of ovulation, Trigger ovulation in assisted reproduction, Preservation of testicular function during exogenous androgen use, Diagnostic assessment of pituitary gonadotropin reserve, Pituitary function diagnostic test, Cryptorchidism treatment. Educational only — not medical advice.
How is Gonadorelin administered?
Recorded routes of administration: Intranasal, Intravenous, Nasal, Subcutaneous.
What are the potential side effects of Gonadorelin?
Reported adverse effects include: Injection site reactions, Multiple gestation, Anaphylaxis / hypersensitivity, Injection site pain, Headache, Flushing, Nausea, Ovarian hyperstimulation syndrome (OHSS). This list is not exhaustive — consult a qualified clinician.
Who should avoid Gonadorelin?
Recorded contraindications: Known hypersensitivity to gonadorelin or formulation excipients, Conditions exacerbated by LH/FSH stimulation (e.g., hormone-sensitive tumors), Hypersensitivity to gonadorelin or GnRH analogues, Pregnancy, Estrogen‑dependent neoplasms (e.g., breast, endometrial cancer), Polycystic ovary syndrome (PCOS) in ovulation induction context. Consult a qualified clinician before use.